IL2 and neoplasm: Tumor-selective IL-2 prodrugs have also recently attracted considerable interest from different research groups for the purpose of increasing intratumoral IL-2 abundance and reducing toxic side effects caused by systemic administration via injection (Table 1; Figure 2C).